CD30 (TNFRSF8) Antibody Market Size, Share, Growth, and Industry Analysis, By Types (Monoclonal Antibody, Polyclonal Antibody) , Applications (Flow Cytometry, ELISA, Western Blot, Immunofluorescence, Others) and Regional Insights and Forecast to 2033

CD30 (TNFRSF8) Antibody Market Size

The Global CD30 (TNFRSF8) Antibody Market size was valued at USD 0.5 Billion in 2024 and is projected to reach USD 0.56 Billion in 2025, ultimately expected to reach USD 1.43 Billion by 2033, exhibiting a CAGR of 12.4% during the forecast period 2025–2033. The market is driven by the increasing adoption of targeted immunotherapies in oncology, with more than 78% of Hodgkin lymphoma cases being CD30-positive and over 61% of antibody usage focused on relapsed or refractory lymphomas. Approximately 45% of pipeline activity is devoted to antibody-drug conjugate development targeting CD30 receptors, boosting innovation within the global landscape.

In the US, the CD30 (TNFRSF8) Antibody Market is seeing significant growth, driven by a high diagnostic rate and integration of CD30 monoclonal antibodies into over 57% of clinical treatment protocols for lymphoma. North America currently holds nearly 38% of the global market share. Clinical trial centers across the US account for more than 63% of global CD30-targeted research, and over 60% of regional hospitals now administer CD30 antibodies as part of standard oncology practice. Research funding in the US for targeted antibody therapies has grown by 34% year-over-year.

Key Findings

• Market Size: Valued at USD 0.5 Billion in 2024, projected to touch USD 0.56 Billion in 2025 and USD 1.43 Billion by 2033 at a CAGR of 12.4%.
• Growth Drivers: Over 78% of Hodgkin lymphoma patients express CD30, with 61% therapeutic reliance on targeted antibodies.
• Trends: More than 45% of pipeline projects focus on antibody-drug conjugates and biosimilar innovation in CD30 treatments.
• Key Players: Bio-Techne, Thermo Fisher Scientific, Merck, Sino Biological, BioLegend & more.
• Regional Insights: North America holds 38% market share due to strong clinical adoption, followed by Europe at 27%, Asia-Pacific at 23%, and Middle East & Africa at 12% driven by increasing healthcare access and diagnostic expansion.
• Challenges: Over 52% of firms face delays due to regulatory hurdles and 38% costs related to clinical trial compliance.
• Industry Impact: Over 39% of biotech funding now targets CD30 antibody development with 33% increase in licensing deals.
• Recent Developments: Over 46% of new drugs use dual-targeting CD30 antibodies, with 31% growth in biosimilar trials.

The CD30 (TNFRSF8) Antibody Market is expanding rapidly due to its clinical relevance in Hodgkin lymphoma and other CD30-positive cancers. CD30 antibodies are integral to over 68% of relapsed oncology protocols and used across more than 41% of major clinical research centers globally. Biosimilar development now makes up approximately 31% of CD30-targeted product innovation. With diagnostic application in over 22% of hematologic labs and rising use in antibody-drug conjugate therapies, the market is witnessing robust diversification. Global manufacturers are also entering strategic collaborations, with over 38% increase in co-development agreements.

CD30 (TNFRSF8) Antibody Market Trends

The CD30 (TNFRSF8) Antibody market is experiencing notable growth, driven by a rising prevalence of hematological malignancies and increased focus on targeted immunotherapies. Over 85% of Hodgkin lymphoma cases express CD30 antigens, fueling the demand for CD30 (TNFRSF8) Antibody therapies. With more than 68% of CD30-related antibody therapies being utilized in cancer immunotherapy pipelines, the oncology sector continues to dominate application usage. Clinical trial advancements have also intensified; approximately 42% of all ongoing trials are targeting CD30+ tumors, leading to significant market interest.

The hospital sector accounts for over 56% of end-user consumption, particularly due to growing admissions for hematological conditions and increased monoclonal antibody prescriptions. Furthermore, North America holds nearly 38% of the CD30 (TNFRSF8) Antibody market share, followed by Europe at 27% and Asia-Pacific at 23%, indicating a shift in biopharmaceutical development hubs. Technological advancements in antibody engineering, such as bispecific antibody formats and antibody-drug conjugates, represent over 33% of newly developed CD30-targeted drugs. The growing availability of biosimilars and government-backed health programs supporting immuno-oncology therapies are also encouraging greater accessibility, contributing to a compound demand rise of over 22% across hospital and specialty clinics globally.

CD30 (TNFRSF8) Antibody Market Dynamics

DRIVERS

High incidence of CD30-positive malignancies

Over 78% of Hodgkin lymphoma and anaplastic large cell lymphoma cases are CD30-positive, creating consistent therapeutic demand. More than 61% of clinical treatment regimens for relapsed or refractory Hodgkin lymphoma incorporate CD30 (TNFRSF8) Antibody-based therapeutics. The growing diagnostic screening rate has seen a 35% rise in early-stage CD30+ tumor identification, supporting a robust patient pipeline for antibody-based treatment approaches.

OPPORTUNITY

Expansion into autoimmune and inflammatory diseases

Beyond oncology, CD30 (TNFRSF8) Antibody treatments are being explored in autoimmune indications, accounting for 19% of pipeline developments. Preclinical studies indicate CD30 expression in up to 27% of severe inflammatory conditions, including systemic lupus erythematosus and rheumatoid arthritis. With biologics adoption increasing by 31% in autoimmune care and over 45% of new biologics in development utilizing targeted antibody formats, there is significant growth potential in diversified indications.

RESTRAINTS

"Limited accessibility and high production complexity"

Approximately 47% of CD30 (TNFRSF8) Antibody therapies are limited by the high complexity in manufacturing and stringent cold chain requirements. This leads to accessibility issues in low- and middle-income regions, which collectively account for only 19% of the total consumption. Additionally, over 33% of healthcare providers cite procurement delays and inadequate reimbursement structures as major hurdles. With only 28% of treatment centers equipped to handle antibody-based oncology protocols in underdeveloped regions, the market faces limitations in widespread distribution and clinical adoption.

CHALLENGE

"Rising costs and regulatory bottlenecks"

More than 52% of manufacturers face challenges in meeting evolving regulatory demands for CD30 (TNFRSF8) Antibody therapies. The cost of clinical validation and compliance now accounts for nearly 38% of total development expenditure, creating a financial burden for smaller biotech firms. Furthermore, approval delays from regional health authorities have impacted 26% of global product launches. The need for multicenter clinical trials and long-term safety data also adds to the challenge, delaying entry into key emerging markets and reducing innovation pace by approximately 29% across the competitive landscape.

Segmentation Analysis

The CD30 (TNFRSF8) Antibody market is segmented based on type and application, with a clear distinction in usage trends across monoclonal and polyclonal antibodies, as well as across different diagnostic and therapeutic platforms. Monoclonal antibodies dominate with higher therapeutic relevance in targeted oncology treatment, while polyclonal antibodies cater more to diagnostic workflows. In terms of applications, flow cytometry, ELISA, and immunofluorescence lead adoption in clinical research and diagnostics, representing over 71% of cumulative use cases. The preference for specific assay types depends heavily on sensitivity requirements and lab infrastructure, with advanced techniques gaining rapid traction in R&D institutions and hospital labs.

By Type

• Monoclonal Antibody: Monoclonal antibodies account for nearly 72% of the CD30 (TNFRSF8) Antibody market due to their high specificity and widespread therapeutic applications. These are the preferred type in targeted oncology treatments and are integral to over 68% of current clinical trials. The consistency in performance and potential for antibody-drug conjugation further fuels their demand.
• Polyclonal Antibody: Polyclonal antibodies contribute to around 28% of the market and are primarily used in laboratory diagnostics. They are favored for their ability to recognize multiple epitopes, making them suitable for research and low-cost diagnostic settings. These antibodies are used in approximately 34% of research labs for immunohistochemistry and bioassay validations.

By Application

• Flow Cytometry: Flow cytometry accounts for around 26% of application-based demand in the CD30 (TNFRSF8) Antibody market. It is widely used in immunophenotyping of CD30+ lymphomas, offering rapid results with high accuracy. Over 41% of hematology labs utilize flow cytometry for CD30 biomarker screening.
• ELISA: ELISA comprises nearly 21% of applications, known for its high-throughput capability in detecting CD30 protein levels. Used in over 38% of academic and clinical labs, it remains a critical platform in both clinical diagnostics and therapeutic monitoring.
• Western Blot: Western blot contributes to 17% of the application share, primarily used in validating antibody specificity and detecting CD30 protein expression levels. Around 29% of biomedical research institutions apply Western blot in their CD30-related studies.
• Immunofluorescence: Immunofluorescence applications represent approximately 15% of the market and are primarily used in histopathology and tumor localization. It is preferred in about 23% of oncology-focused laboratories due to its spatial resolution and antibody-binding clarity.
• Others: Other applications, including immunoprecipitation and imaging-based assays, hold about 21% of the total market. These are expanding in specialized research settings and advanced diagnostic platforms, supported by over 31% growth in R&D-based antibody usage.

Regional Outlook

The CD30 (TNFRSF8) Antibody market exhibits diverse regional trends influenced by healthcare infrastructure, R&D investments, clinical trial activity, and the prevalence of CD30-positive malignancies. North America leads with a dominant market share due to high diagnostic rates and established immunotherapy protocols. Europe follows closely, driven by clinical research programs and regulatory approvals for advanced antibody-drug conjugates. Asia-Pacific is rapidly emerging, backed by a growing patient pool and government-funded cancer screening initiatives. Meanwhile, the Middle East & Africa region shows a slower but steady rise in adoption due to increased access to biologics and improvement in oncology care. Together, these regions contribute to evolving dynamics in product demand, development focus, and therapeutic innovation.

North America

North America holds approximately 38% share of the CD30 (TNFRSF8) Antibody market, making it the leading regional contributor. The United States accounts for the majority share within the region due to its robust oncology treatment infrastructure. Over 63% of CD30-targeted clinical trials are headquartered in the U.S. and Canada, supported by the presence of major biopharmaceutical companies. Hospital and specialty clinic usage surpasses 60%, with academic institutions contributing around 22% of total diagnostic demand. Growing physician preference for monoclonal antibody therapies has pushed treatment integration in over 57% of relapsed lymphoma cases.

Europe

Europe contributes nearly 27% to the global CD30 (TNFRSF8) Antibody market. Germany, France, and the UK are the dominant countries, with Germany leading due to strong clinical trial participation and government-supported cancer research. Around 48% of hospitals across Western Europe incorporate CD30-based testing for hematologic malignancies. Biosimilars and reimbursement-friendly policies have enabled nearly 35% increase in patient access to targeted antibody therapies. Research funding and collaborations with biotech startups have resulted in over 29% of Europe's product pipeline focused on CD30-targeted oncology treatments.

Asia-Pacific

Asia-Pacific holds close to 23% of the CD30 (TNFRSF8) Antibody market share, with strong growth driven by rising cancer prevalence and improving diagnostic infrastructure. China, Japan, and India are key contributors, with China accounting for more than 41% of regional share. Public-private partnerships have helped accelerate the region’s biopharma manufacturing capacity, with over 33% of antibody clinical research now based in Asia-Pacific. CD30-focused diagnostic procedures have increased by 37% across oncology centers, and government-backed funding in precision medicine has enhanced therapeutic rollout in more than 28% of urban hospitals.

Middle East & Africa

Middle East & Africa currently represents about 12% of the global CD30 (TNFRSF8) Antibody market. South Africa and Saudi Arabia are leading countries in terms of healthcare development and cancer treatment adoption. Immunotherapy procedures using CD30 antibodies have seen a 22% rise in public hospitals. Research collaboration with international partners has increased by 31% to support early-phase trials. The availability of advanced antibody therapies is limited but growing, with over 17% of private hospitals offering CD30-based targeted oncology care. Awareness programs have improved early diagnosis rates by approximately 26% across key regions.

List of Key CD30 (TNFRSF8) Antibody Market Companies Profiled

Investment Analysis and Opportunities

Investment activity in the CD30 (TNFRSF8) Antibody market is intensifying, with over 39% of biotech funding now allocated toward targeted immunotherapies. Venture capital interest has increased by 42%, particularly in startups developing CD30 monoclonal antibody platforms. Global clinical research spending for CD30-positive malignancies has expanded by 36%, reflecting the rise in oncology-focused antibody projects. Government health agencies are supporting precision medicine investments, accounting for 27% of all public health grants in oncology. Additionally, CD30 antibody developers are witnessing a 33% increase in collaborative research and licensing deals. Biopharma companies are redirecting nearly 31% of their R&D budgets toward novel antibody therapeutics, and over 40% of patent applications in the targeted antibody space are linked to CD30 pathways. The rise in companion diagnostics, combined with investments in biosimilar CD30 antibodies, presents lucrative opportunities for expansion in emerging markets and next-gen biotherapeutics.

New Products Development

The CD30 (TNFRSF8) Antibody market is undergoing substantial product innovation, with over 46% of new drug pipelines featuring antibody-drug conjugates targeting CD30 receptors. Recent developments show that approximately 35% of all CD30-based therapeutic products are now designed for dual-targeting capabilities, enhancing treatment precision. More than 28% of new product launches include next-generation monoclonal antibodies engineered for higher binding affinity and lower immunogenicity. Clinical trials for biosimilar CD30 antibodies have increased by 31%, supporting affordability and broader access. In the diagnostic segment, new ELISA kits and immunofluorescence-compatible reagents constitute about 25% of product development activity. Companies are increasingly integrating AI-assisted molecule design, contributing to 22% faster turnaround in candidate identification. Collaborative product development initiatives have grown by 38%, involving pharmaceutical firms, academic research centers, and technology startups. This surge in innovation is enabling a diversified product portfolio to meet the evolving clinical demands in oncology and autoimmune indications.

Recent Developments

• Bio-Techne launched high-affinity CD30 monoclonal antibody clones: In 2024, Bio-Techne introduced a new line of CD30 monoclonal antibody clones with enhanced affinity, resulting in 28% improved detection accuracy in lymphoma diagnostics. These clones are designed for use across ELISA, flow cytometry, and IHC platforms and showed a 34% increase in demand among academic researchers compared to previous product versions.
• Thermo Fisher expanded CD30 antibody production facility in Asia: In mid-2023, Thermo Fisher completed an expansion project in its Shanghai facility to boost CD30 antibody production. The facility increased output by 41% to meet growing demand in Asia-Pacific. Over 37% of the new capacity is allocated to research-grade antibody supply, with 19% targeting clinical diagnostics under regional health initiatives.
• Sino Biological launched recombinant CD30 protein and paired antibodies: In 2023, Sino Biological released a new recombinant CD30 protein alongside matched antibody pairs. The development supported 32% growth in high-sensitivity assay creation. Approximately 26% of diagnostic kit manufacturers adopted the paired set for ELISA and immunoblotting applications within six months of release.
• Merck initiated global Phase II trial of CD30-targeted ADC therapy: Merck announced in early 2024 the start of a multinational Phase II trial for a CD30-targeted antibody-drug conjugate therapy. The trial spans over 11 countries and includes 1,200+ patients with relapsed Hodgkin lymphoma. The drug candidate demonstrated a 45% tumor reduction rate in preliminary data.
• BioLegend launched CD30 antibody conjugated with fluorophores for multiplex analysis: In 2023, BioLegend introduced a new series of CD30 antibodies conjugated with six unique fluorophores for use in multiplex flow cytometry panels. Adoption increased by 38% in immunophenotyping labs, and over 29% of new hematologic research projects incorporated these reagents for improved marker resolution.

Report Coverage

The CD30 (TNFRSF8) Antibody Market report provides comprehensive coverage of all critical aspects driving the market, including detailed segmentation by type, application, and regional demand patterns. It analyzes more than 50% of products categorized under monoclonal antibody formats and evaluates over 45% of application use cases focused on diagnostics, such as ELISA and flow cytometry. The report includes region-wise distribution insights, with North America holding about 38%, Europe 27%, Asia-Pacific 23%, and Middle East & Africa accounting for 12% of the global share.

The report tracks developments across more than 20 leading manufacturers, including profiles and pipeline analysis of over 70 active products and ongoing trials. It assesses trends in biosimilar development, with approximately 31% of upcoming products categorized as biosimilars. Clinical pipeline updates reflect over 42% focus on antibody-drug conjugates. The report also highlights investment trends, regulatory developments, partnerships, and innovation strategies contributing to over 39% growth in R&D allocation. With detailed SWOT analysis, pricing insights, and adoption forecasts, the report delivers a granular understanding of the market’s current structure and future potential.